It’s time to rethink defense against RSV.

mRESVIA® (Respiratory Syncytial Virus [RSV] mRNA Vaccine) is indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults 60 years of age and older, and adults 18 through 59 years of age who are at increased risk for LRTD caused by RSV.¹

People at higher risk of developing severe illness include:²

• older adults
• adults with certain chronic medical conditions, including:
  • asthma
  • diabetes
  • heart disease
  • chronic obstructive pulmonary disease (COPD)
• those who are immunocompromised
• those who live in long-term care or other chronic care facilities

NACI strongly recommends RSV immunization for all adults:³

• aged ≥75 years and those aged 65–74 years who are at increased risk of severe RSV disease
• aged ≥18 years who:
  • are residents of nursing homes and other chronic care facilities
  • have had a lung transplant
  • have had a hematopoietic stem cell transplant (in the previous two years or who remain on immunosuppression)
  • are on home oxygen or require chronic oxygen therapy regardless of living at home or elsewhere
  • are receiving dialysis

Discretionary recommendation

For other adults who may seek vaccination outside of a public health program, NACI recommends that RSV vaccines may be considered by adults 18−64 years of age at increased risk of severe RSV disease as an individual decision informed by discussion with their health care provider. A careful assessment of benefits versus potential harms is warranted, as most younger adults may benefit more from vaccination at an older age or if they develop a condition that increases their risk for severe RSV disease.³

The most commonly reported (≥15%) solicited adverse reactions (local and systemic) within 7 days of vaccination in subjects aged ≥60 years were injection site pain (55.9% vs. 13.8% placebo), fatigue (30.8% vs. 20.0% placebo), headache (26.7% vs. 18.8% placebo), myalgia (25.6% vs. 14.4% placebo), arthralgia (21.7% vs. 14.0% placebo) and axillary swelling or tenderness (15.2% vs. 6.1% placebo).¹

The most commonly reported (≥15%) solicited adverse reactions (local and systemic) within 7 days of vaccination in subjects aged 18–59 years at increased risk for LRTD caused by RSV were injection site pain (73.9%), fatigue (36.9%), headache (33.3%), myalgia (28.9%), arthralgia (22.7%), chills (19.9%) and axillary swelling or tenderness (17.1%).¹

Most solicited local and systemic adverse reactions had onset within 1–2 days after injection and a median duration of 2 days.¹

Refer to the Product Monograph for additional safety information.

Medicinal ingredients:¹

50 mcg of mRNA encoding RSV glycoprotein F stabilized in the prefusion conformation, 5′(m7G-5′-ppp-5′-Gm) cap, 100-nucleotide 3′ poly(A) tail

Non-medicinal ingredients:¹

• Acetic acid
• Cholesterol
• DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine)
• SM-102 (heptadecan-9-yl 8-([2-hydroxyethyl] [6-oxo-6-(undecyloxy) hexyl] amino) octanoate)
• PEG2000-DMG (1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000)
• Sodium acetate trihydrate
• Sucrose
• Trometamol
• Trometamol hydrochloride
• Water for injection

As studies are ongoing, concomitant administration of mRESVIA with other vaccines are unknown. No interaction studies have been performed.¹

If administering mRESVIA at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites. Do not mix mRESVIA with other vaccines/products in the same syringe.¹

Please follow the guidelines for the storage and handling of the vaccines to ensure their efficacy.

mRESVIA Quick Reference DASH Guide

mRESVIA Product Monograph

No, thawed vaccines cannot be refrozen.¹

Once thawed, pre-filled syringes can be stored refrigerated between 2° to 8°C for up to 90 days prior to first use.¹